ERBB2 and breast cancer: The future results of the randomized phase 2 study AVIATOR (NCT03414658) of Utomilumab to target 4-1BB in combination with avelumab and trastuzumab in patients that progressed to prior trastuzumab and pertuzumab will set the expectations of complex immunotherapy combinations in HER2 BC.